Salarius Pharmaceuticals, Inc.

NASDAQ (USD): Salarius Pharmaceuticals, Inc. (SLRX)

Last Price

1.62

Today's Change

-0.04 (2.40%)

Day's Change

1.62 - 1.67

Trading Volume

39,125

Overview

Market Cap

2 Million

Shares Outstanding

1 Million

Avg Volume

2,158,845

Avg Price (50 Days)

1.91

Avg Price (200 Days)

2.19

PE Ratio

-0.32

EPS

-5.14

Earnings Announcement

20-Mar-2025

Previous Close

1.66

Open

1.67

Day's Range

1.62 - 1.67

Year Range

1.22 - 7.2

Trading Volume

39,125

Price Change Highlight

1 Day Change

-2.41%

5 Day Change

-10.50%

1 Month Change

-39.78%

3 Month Change

20.90%

6 Month Change

-14.74%

Ytd Change

-6.90%

1 Year Change

-64.16%

3 Year Change

-98.16%

5 Year Change

-99.10%

10 Year Change

-100.00%

Max Change

-100.00%

News and Blogs

No result.

Company Profile

Sector: Healthcare - Healthcare

Industry: Biotechnology

Description:

Salarius Pharmaceuticals, Inc., a clinical-stage biotechnology company, focuses on developing epigenetic-based cancer treatments. Its lead candidate is Seclidemstat (SP-2577), a small molecular inhibitor which is in Phase I/II clinical trial for the treatment of advanced solid tumors, as well as Ewing sarcoma. The company also offers SP-3164, a small molecular protein degrader for the treatment of hematological and solid tumors. It has a strategic partnership with The University of Utah Research Foundation for the exclusive license with respect to patent rights protecting SP-2577 and related compounds; HLB Life Sciences to develop, produce, manufacture, use, and sell the drug in South Korea; and Cancer Prevention and Research Institute of Texas for product development activities, as well as a research partnership with the Cancer Epigenetics Institute at Fox Chase Cancer Center to identify new indications and biomarkers for SP-2577. The company is headquartered in Houston, Texas.

Discussions
Be the first to like this. Showing 0 of 0 comments

Post a Comment